Cargando…

Checkpoint Responses in Cancer Therapy

Extensive research has uncovered a set of molecular surveillance mechanisms - commonly called "checkpoints" - which tightly monitor cell-cycle processes. Today's anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Dai, Wei (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Totowa, NJ : Humana Press : Imprint: Humana, 2008.
Edición:1st ed. 2008.
Colección:Cancer Drug Discovery and Development,
Temas:
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-1-59745-274-8
003 DE-He213
005 20220112194155.0
007 cr nn 008mamaa
008 100301s2008 xxu| s |||| 0|eng d
020 |a 9781597452748  |9 978-1-59745-274-8 
024 7 |a 10.1007/978-1-59745-274-8  |2 doi 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
082 0 4 |a 571.978  |2 23 
082 0 4 |a 616.994  |2 23 
245 1 0 |a Checkpoint Responses in Cancer Therapy  |h [electronic resource] /  |c edited by Wei Dai. 
250 |a 1st ed. 2008. 
264 1 |a Totowa, NJ :  |b Humana Press :  |b Imprint: Humana,  |c 2008. 
300 |a XIV, 314 p. 33 illus., 3 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Cancer Drug Discovery and Development,  |x 2196-9914 
505 0 |a RB-Pathway -- Targeting the p53/MDM2 Pathway for Cancer Therapy -- DNA Topoisomerases as Targets for the Chemotherapeutic Treatment of Cancer -- Targeting ATM/ATR in the DNA Damage Checkpoint -- Compounds that Abrogate the G2 Checkpoint -- CDK Inhibitors as Anticancer Agents -- CHFR as a Potential Anticancer Target -- Antimicrotubule Agents -- Kinesin Motor Inhibitors as Effective Anticancer Drugs -- Targeting the Spindle Checkpoint in Cancer Chemotherapy -- Antiproliferation Inhibitors Targeting Aurora Kinases -- Plks as Novel Targets for Cancer Drug Design -- Do Histone Deacetylase Inhibitors Target Cell Cycle Checkpoints that Monitor Heterochromatin Structure?. 
520 |a Extensive research has uncovered a set of molecular surveillance mechanisms - commonly called "checkpoints" - which tightly monitor cell-cycle processes. Today's anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book's distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis. 
650 0 |a Cancer. 
650 0 |a Pharmacology. 
650 1 4 |a Cancer Biology. 
650 2 4 |a Pharmacology. 
700 1 |a Dai, Wei.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9781603277976 
776 0 8 |i Printed edition:  |z 9781617378478 
776 0 8 |i Printed edition:  |z 9781588299307 
830 0 |a Cancer Drug Discovery and Development,  |x 2196-9914 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-1-59745-274-8  |z Texto Completo 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708)